curriculum vitae personal data name: evan todd keller, … › ~etklab › personnel › resume ›...

CURRICULUM VITAE

PERSONAL DATA Name: Evan Todd Keller, D.V.M., Ph.D., M.P.V.M.

EDUCATION

1983 University of California-Davis, Davis, California; B.S. (Veterinary Science) 1985 University of California-Davis, Davis, California; D.V.M. (Veterinary

Medicine) 1985 University of California-Davis, Davis, California; M.P.V.M. (Masters

Preventive Veterinary Medicine-Epidemiology) 1996 University of Wisconsin-Madison, Madison Wisconsin; Ph.D. (Developmental

Biology)

RESIDENCY TRAINING 1990-1992 University of Wisconsin-Madison, Madison, Wisconsin (Veterinary Oncology)

POSTDOCTORAL TRAINING

1992-1995 National Institutes of Health Post-doctoral Fellow, University of Wisconsin-Madison, Madison, Wisconsin (Molecular Endocrinology)

ACADEMIC APPOINTMENTS

1992-1994 Epidemiologist, Bernese Mountain Dog Cancer Study 1995-1996 Assistant Research Scientist, University of Wisconsin-Madison 1996-1998 Assistant Professor, Medicine and Pathology, Eastern Virginia Medical School 1996-1998 Director of Laboratory, Glennan Center for Geriatrics 1998-2001 Assistant Professor of Comparative Medicine, Unit for Laboratory Animal

Medicine, University of Michigan Medical School 1998-2001 Assistant Professor of Pathology, Dept. of Pathology, University of Michigan

Medical School 1999-2003 Assistant Research Scientist, Institute of Gerontology, University of Michigan 1999-present Honorary Professor, Dept. of Immunology, Tianjin Medical University,

Tianjin, China 2001-2005 Associate Professor, Dept. of Pathology and Unit for Laboratory Animal

Medicine, University of Michigan Medical School 2003-present Research Associate Professor, Institute of Gerontology, University of Michigan 2004-2005 Associate Professor, Dept. of Urology, University of Michigan Medical School 2005-present Professor, Dept. of Pathology and Unit for Laboratory Animal Medicine,

University of Michigan Medical School 2005-present Professor, Dept. of Urology, University of Michigan Medical School

CONSULTING POSITIONS 1997 K. Kregel, PI. University of Iowa. RO1 NIA, “Oxidative Stress and Aging:

Integrated Mechanisms." 1999-2000 Parke-Davis (now Pfizer) Pharmaceuticals, Bone biology. 2002-2006 Centocor 2002-current Amgen 2003-current MedeaCorp 2003 Vertex Pharmaceuticals 2003-2005 Northwest Airlines 2004-2009 Eisai Pharmaceuticals 2004-2006 Pfizer

Curriculum Vitae: Evan T. Keller DVM, PhD

2007-current Lilly 2008-2009 Merck 2007-current Bone metastases P01 University of Washingtion, R. Vessella PI. 2010-current Myeloma P01 EAB, D. Roodman, U. Pittsburgh

SCIENTIFIC ACTIVITIES Journals

1994 -present Ad hoc reviewer, Journal Veterinary Internal Medicine 1995 -present Ad hoc reviewer, Journal of Gerontology: Biological Sciences 1996 - 1999 Deputy Editor, Journal of Gerontology: Medical Sciences 1996 Ad hoc reviewer, Life Sciences 1996 Ad hoc reviewer, Oncology 1998-present Ad hoc reviewer, Cancer Research 1999 Ad hoc reviewer, Cytokine 2000-present Ad hoc reviewer, Hormone and Metabolic Research 2000-present Ad hoc reviewer, Urology 2001-present Ad hoc reviewer, The Prostate 2001-present Ad hoc reviewer, Journal of Clinical Investigation 2001-present Ad hoc reviewer, Clinical Cancer Research 2002-present Ad hoc reviewer, Neoplasia 2002 Ad hoc reviewer, Journal of Veterinary Internal Medicine 2002 Ad hoc reviewer, Veterinary Medicine 2003-present Ad hoc reviewer, Molecular Cancer Research 2003-present Ad hoc reviewer, Journal Bone Mineral Research 2004 Ad hoc reviewer, Acta Pharmacologica Sinica 2004 Ad hoc reviewer, International Journal of Cancer 2004 Ad hoc reviewer, Journal of Urology 2005-present Editorial Board member, Journal of Cellular Biochemistry 2005 Ad hoc reviewer, Nature Clinical Practice Oncology 2006-present Editorial Board member, Current Cancer Drug Targets 2006 Ad hoc reviewer, Asian Journal of Urology 2006 Ad hoc reviewer, British Journal of Cancer 2006 Ad hoc reviewer, Cancer Biology Therapeutics 2006 Ad hoc reviewer, Peptides 2006 Ad hoc reviewer, Cancer Chemotherapy Pharmacology 2006 Ad hoc reviewer, Cancer Immunology Therapeutics 2006 Ad hoc reviewer, Cancer Metastasis Reviews 2006 Ad hoc reviewer, Carcinogenesis 2006 Ad hoc reviewer, Gene, Chromosomes, Cancer 2006 Ad hoc reviewer, Lancet 2006 Ad hoc reviewer, Journal Pharmacological and Experimental Therapeutics 2006 Ad hoc reviewer, Microvascular Research 2006 Ad hoc reviewer, Urologic Oncology 2006 Ad hoc reviewer, Nephrology and Dialysis 2008 Ad hoc reviewer, Clinical Genetics 2008 Ad hoc reviewer, Molecular Cancer Therapy 2008 Ad hoc reviewer, Molecular Cancer Research 2008 Ad hoc reviewer, Peptides 2008 Ad hoc reviewer, Cancer Letters 2008 Ad hoc reviwer, Gerontology 2008-present Editorial Board member, Cancer Management and Research 2008-present Editorial Board member, Clinical Medicine Insights: Urology


Grant Reviews

1997-2005 External Scientific Grant Reviewer, VA Merit Review Board, Department of Veterans Affairs

1997-2003 Ad hoc reviewer, U.S. Army Osteoporosis Grants 1997 Ad hoc reviewer, EVMS Institutional Grants 1998-present American Federation for Aging Research 2000 Office of Vice President for Research, U.M. 2000 NIH: Special Emphasis Panel, NIA Claude Pepper Center Reviews 2001 NIH: NIAAA: Special Emphasis Panel, Microarray based research on alcohol's

effects on behavior, nervous system function and organ pathophysiology. 2001-2003 Department of Defense Section C Review Panel: Osteoporosis Grants 2001 NIH: Caloric restriction Special Emphasis Panel 2001 American Kennel Club Canine Research Grants 2001-present Department of Defense Pathology B: Prostate Cancer Grants 2002-present NIA: Program Project Reviews 2002 Ohio Cancer Research Foundation 2003- NIH: Comparative Biology of Aging Special Emphasis Panel 2004 NIH, SIBR Cancer Therapy 2004-2010 Member of Tumor microenvironment (TME) for NIH 2007 Ohio Cancer Foundation 2007 MFI Medizinische Forschungsförderung Innsbruck 2008 National Medical Research Council of Singapore 2010 Department of Defense Prostate Cancer Training Grants 2011 P01 Special Emphasis Panel 2011 Department of Defense Prostate Cancer Hypothesis Grants Meeting Organization 1998 Chair, Bone biology section: Serono Symposium on Menopause, Newport

Beach, CA. 2002 Organization Committee, Biology of Aging Symposia. The second

international conference on aging and geriatrics. Washington DC. 2002 Chair, Basic Biology of Aging Symposia at he second international conference

on aging and geriatrics. Washington DC. 2003 Organizer, Connective Tissue Oncology Symposia, University of Michigan 2004 Discussion Leader, Nathan Shock Center Meeting on Animal Models of Aging,

University of Michigan. 2004 Chair, Prostate Cancer Session, 9th World Congress on Advanced in

Oncology, Crete, Greece. 2004 Chair, Bone Metastasis Session, Prouts Neck Prostate Cancer Conference,

Prouts Neck, ME. 2005 Chair, Bone Metastasis Session, InterProstate SPORE meeting, Houston, TX. 2006 Organization Committee, Prouts Neck Prostate Cancer Meeting, 2006. 2006 Discussion Leader, Poster Discussion Session on Prostate Pathobiology,

American Society of Clinical Oncology Meeting, Atlanta, GA 2006 2007 Combined P01 meeting of U. Washington, Emory U. and U. Michigan, Ann

Arbor, MI 2007 2010 Co-Director, Prostate Oncology Program, 11th Annual Weisbach Lecture,

University of Michigan. 2011 Co-Direcrtor, Prostate Oncloogy Program, 12th Annual Weisbach Lecture,


University of Michigan 2012 Organizer, Combined P01 meeting of Emory U., Fred Hutchinson Cancer

Research Center, MD Anderson, U. Delaware, U. Michigan, U. Washington, Van Andel Institute, Wayne State U.

2013 Chair, NIH Study Section: Shared Instrumentation: Genomics July 2013.

U. Michigan 1999-current Director, Bone metabolism core, Program in Comparative Integrative

Genomics 1999-current Member, Michigan Comprehensive Cancer Center 1999-current Faculty, Graduate Program in Cellular and Molecular Biology 1999-current Faculty, Graduate Program in Immunology 1999-current Member, Multipurpose Arthritis and Musculoskeletal Disease Center 1999-2004 Director, NCRR Training Grant on Training Veterinarians as Biomedical

Scientists 2000-2002 Co-Director, Program in Connective Tissue Oncology, U.M. Cancer Center 2000-current Director, Nathan Shock Center Mutant & Transgenic Rodent Core 2003-2009 Co-Director, Cancer Biology Program, U.M Comprehensive Cancer Center 2009-current Co-Director, Prostate Oncology Program, UM Comprehensive Cancer Center

FUNDING COMPLETED FUNDING

University of Wisconsin School of Veterinary Medicine Companion Animal Fund. “Particle-bombardment gene therapy in the dog.” (MacEwen, PI; Keller Co-PI), 1992 ($20,000 total).

American Federation for Aging Research (A96169) “Androgen’s Effect on Interleukin-6 Expression in Bone Cell Lines.” (Keller; PI), 7/1/96-6/30/97 ($40,000 total).

Virginia Center on Aging, “Do free radicals induce interleukin-6 expression in the rat hippocampus? A model for Alzheimer’s disease.” (Keller; PI) 6/97-5/98, ($16,500 total).

National Institutes of Health (RO1-AG-11970-Supplement). “Minority supplement to the parent grant: Interleukin-6 and Osteoporosis.” (Keller; Role: PI) 5/1/97-4/30/98. ($50,000 annual direct costs).

National Institute of Aging (R01-AG-11970), “Interleukin-6 and Osteoporosis” (Keller; PI), 5/1/95-4/30/01 ($228,827 annual direct cost).

U. Michigan Cancer (Center Summer Student Research Grant) “Role of interleukin-6 in prostate cancer bone metastases.” (Keller:PI; Dai Student) 06/01/99-08/31/99, ($2,500).

U. Michigan BMRC (Equipment Grant). Light Cycler PCR Machine (Keller; Role: PI). 04/01/00 ($48,175 annual direct cost).

Parke-Davis Pharmaceuticals, (Gift)(Keller: PI) “For Bone Biology Research Development” , 10/01/99-current ($50,000).

U. Michigan SPORE in Prostate Cancer. "Role of AKT kinase in androgen-independent prostate cancer, Z. Fu Student Award. (Keller; Role: PI Mentor) 08/01/00-07/31/01 ($5,000 annual direct costs).

U. Michigan SPORE in Prostate Cancer. "Role of osteoprotegerin in prostate cancer, J. Zhang Student Award. (Keller; Role: PI Mentor) 08/01/00-07/31/01 ($5,000 annual direct costs).

U. Michigan SPORE in Prostate Cancer Summer Student Award (Student: Mary Whitney) (Keller Role: PI Mentor) $5,000.

U. Michigan SPORE in Prostate Cancer Summer Student Award (Student: Zheng Fu) (Keller Role: PI Mentor) $5,000.

UROP Summer Student Award (Student: Mary Whitney) (Keller Role: PI Mentor) $2,500. National Institute of Aging (R01-AG-15904), Supplement for “Ethanol-mediated osteoporosis

and interleukin-6.” (Keller, PI) 12/15/98-12/14/01 ($61,000 annual direct cost).


National Cancer Institute. SPORE in Prostate Cancer. “Inhibition of interleukin-6 to enhance prostate cancer chemotherapy.” (Keller, PI), 10/01/99-9/28/00. ($45,000 annual direct cost).

National Institute of Aging (R01-AG-15904), “Ethanol-mediated osteoporosis and interleukin-6.” (Keller, PI) 3/1/98-2/28/03 ($148,000 annual direct cost).

U. Michigan BMRC (Basic Science Program Project Planning Grant) “The biology of prostate cancer skeletal metastases.” (Keller; Role: PI), 10/01/99-04/30/01 ($10,000 annual direct cost).

Immunex (Gift) (Keller: PI) “For prostate cancer bone metastases research”10/01 ($40,000). Department of Defense. (DAMD17-00-1-053) “Interleukin-6 and prostate cancer progression.”

(Keller, PI) 06/01/00-05/30/03 ($69,000 annual direct cost). National Institute of Aging. (R01-AG-15884) “Aging, gene expression and oxidative stress”

(Keller; PI) 12/01/99-11/30/02 ($170,000 annual direct cost). National Center for Research Resources. (T32 RR-07008-21) “Biomedical Research Training for

Veterinary Scientists.” (Keller, PI) through-1/30/04 ($260,000 annual direct cost) CapCURE Foundation (Keller: PI 1/02 ($75,000)“Targeting prostate cancer bone metastases” Stuart and Barbara Padnos Endowed Research Fund of the University of Michigan

Comprehensive Cancer Center “A prostate cancer metastasis suppressor gene” (Keller:PI) 05/02-04/03 ($50,000)

Department of Defense (DAMD17-03-1-0092 )(Keller, PI)“Targeting Osteoclastogenesis in Prostate Cancer Skeletal Metastasis” 02/01/03-001/31/05 ($330,000 total cost).

National Institute on Aging. (P30-AG-13283) “Nathan Shock Center, Biology of Aging.” (J. Faulkner, PI; Keller, Director Mutant and Transgenic Rodent Core) 07/01/00-06/30/05. ($84,889 core annual direct cost).

National Cancer Institute (P30-CA-46592), (M. Wicha, P.I., Keller, Associate Director of Cancer Biology Program: Supemphasis on metastasis and angiogenesis) 06/01/01-05/31/06 ($1,865,046 annual direct cost).

Natonal Cancer Institute (R01 CA103109) (Keller, PI) VEGF and bone remodeling in skeletal metastases. 11/01/03-10/31/06 ($225,000 annual direct cost).

National Institute of Aging (R01-AG-21866) (Keller, PI) “Development of Mature Zebrafish as an Animal Model.” 06/01/02-5/30/07 ($250,000 annual direct cost).

National Institute on Aging. (P30-AG-13283) “Nathan Shock Center, Biology of Aging.” (J. Faulkner, PI; Keller, Director of Mutant and Transgenic Rodent Core) 07/01/05-06/30/10 ($58,000 core annual direct cost).

National Cancer Institute (P30-CA-46592),(M. Wicha, P.I.; Keller, Co-Director of Cancer Biology Program: Supemphasis on metastasis and angiogenesis) 06/01/06-05/31/11 ($3,415,190 annual direct cost).

National Cancer Institute (P50-CA69568), (K. Pienta, Program PI; E. Keller Project PI) SPORE in Prostate Cancer. Keller’s Project: The role of bone resorption in prostate cancer skeletal metastases. 7/01/03-7/13/08 ($160,000 annual direct cost).

Centocor Research contract (Keller, PI) “Targeting interleukin-6 in prostate cancer progression” 9/01/03-8/31/04 ($230,000 total cost).

National Cancer Institute (P01 CA093900) (E. Keller, Program PI) The biology of prostate cancer skeletal metastases. 06/01/04-05/30/09 ($1,004,000 annual direct cost. $8,000,000 total costs. THIS IS A PROGRAM PROJECT).

American Kennel Club (Comstock, PI; Keller Co-PI). Mapping genes associated with osteosarcoma in large dog breeds. 03/01/05-02/28/07 ($141,770 annual direct cost).

National Cancer Institute (R01CA098513) (E. Keller, PI) Prostate Cancer Metastasis Suppressor: Role of RKIP. 03/01/04-02/28/10 ($162,000 annual direct cost).

U. Michigan Comprehensive Cancer Center (E. Keller, PI) Affect of the tumor microenvironment on cancer stem cells. 3/07-3/08 $50,000

U. Michigan Comprehensive Cancer Center (E. Keller, PI) GM-CSF in breast cancer bone


metastasis. $50,000 U. Michigan Comprehensive Cancer Center (E. Keller, PI) Genetic Mutations Associated with

Increased Risk for Osteosarcoma. $50,0000 Merck (E. Keller, PI) SAHA as an adjuvant to taxotere in prostate cancer . 07-08 Eisai Pharmaceuticals. (E. Keller, PI) E6070 in prostate cancer bone metastasis. Pfizer (Keller, PI) Post-doctoral satellite training in bone metastasis (11/08-10/10) $360,000. Lilly Pharmaceuticals. (Keller, PI) DKK-1 inhbition of prostate cancer bone metastasis.

ACTIVE FUNDING

NCI (P01 CA-093900) (Keller PI) Program Project: The biology of prostate cancer skeletal metastasis. 05/2009-04/2014 ($980,000 annual direct costs).

National Institute on Aging. (P30-AG-13283) “Nathan Shock Center, Biology of Aging.” (R.

Miller, PI; Keller, Director, Aging Rodent Core) 07/01/05-06/30/10. ($84,889 core annual direct cost).

NCI (R01 CA125577) (C. Kleer, PI; Keller Co-I). Role of CCN6 (WISP3) in the Progression and

Metastasis of Breast Cancer . 9/2008-7/2013. ($207,500 annual directs). Department of Defense PC081459 (Keller, PI). Novel aptamers to target metastasis. 9/2009-

11/2012. ($122,000 annual directs). NCI (P30CA046592) (M. Wicha, PI; Keller, Program Director). Cancer Center Support Grant;

Co-Director of Prostate Oncology Program. 06/2006-05/2012. Dompe Pharmaceuticals. (Keller, PI) Targeting Prostate cancer stem cells. 4/2011-4/2012

($110,000 directs) Dompe Pharmaceuticals (Keller, PI) Targeting Bladder cancer stem cells. 4/2011-4/2012

($120,000 directs) . Exelixis Pharmaceuticals (Keller, PI) XL184 in prostate cancer bone metastasis 2/2011-1/2011

($120,000 directs). Astra Zeneca (Keller, PI) Wnt pathway in prostate cancer bone metastasis 6/2011-5/2012

($60,000 directs). National Center for Research Resources (S10RR026405) (Keller, PI) IVIS imaging system

equipment grant. 02/2010-01/2011. ($360,000 total directs) NCI (R01CA133479) (K. Yeung, PI; Keller Co-I). RKIP regulation as a potential for tumor

suppression. 07/2009-06/2011. NCI (R01CA133620) (W. Zou, PI; Keller, Co-I) Regulatory T cells and tumor bone marrow

metastasis. 08/2009-07/2011. ($207,000 annual direct costs). Health & Human Services, NIH (2-R01-CA-129765-06-A1) Wicha, M, PI; Keller, Co-I) HER2

Regulation of Luminal Breast Cancer Stem Cells. 7/2/2013 to 4/30/2018. ($250.00 directs)


CERTIFICATION AND LICENSURE

1985 Licensed to practice veterinary medicine, #9123, California 1990 Licensed to practice veterinary medicine, #3520, Wisconsin 1993 Board Certification: American College of Veterinary Internal Medicine Subspecialty:

Oncology 2001 Licensed to practice veterinary medicine, #6901008777, Michigan

HONORS AND AWARDS

1994 Smith-Kline Beecham Outstanding Oral Presentation Award. American College of Veterinary Internal Medicine Annual Meeting, San Francisco, CA.

1995 Finalist, George Sacher Award for outstanding abstract. Geriatric Society of America Annual Meeting, Los Angeles, CA.

1995 Agracetus, Inc., Collaborator Travel Award. Middleton, WI. 1996 Mentored Dave Hall; Outstanding Abstract Award for Paper Presentation: Eastern

Virginia Medical School Annual Research Conference. 1996 Mentored Jian Zhang; Annual Meeting Poster Award for Outstanding Geriatrics

Research in Physiology, Cellular and Molecular Biology for the poster. American Geriatric Society annual meeting. Chicago, IL.

1996 John A. Hartford Foundation Student Travel Award. The American Geriatric Society/American Federation for Aging Research Annual Meeting. Chicago, IL.

1996 New Investigator Award for Outstanding Achievement in Biological Aging Research. Institute on Aging, 8th Annual Colloquium. University of Wisconsin-Madison, WI.

1997 Mentored Jian Zhang; Young Investigator Award. Oxygen Society Annual Meeting, San Francisco, CA.

1997 Mentored Dave Hall; Finalist for the George Sacher Award. Gerontological Society of America Annual Meeting, Cincinnati, OH.

1997 Mentored Dave Hall; Platform Presentation: Eastern Virginia Medical School Annual Research Conference.

1997 Permanent Membership to the Frontiers of Bioscience Society of Scientists. 1998 Merck US Human Health/American Geriatrics Society New Investigator award.

American Geriatrics Society, Seattle, WA. 1999 Appointed Honorary Professor of Immunology, Tianjin Medical University, Tianjin

China. 1999 Outstanding Paper Presentation, International Osteoporosis Society, Xian, China 1999 Presidential Poster Award, American Geriatric Society Annual Meeting 2000 Visiting Professorship, Dept. of Immunology, Tianjin Medical University, Tianjin

China. 2000 Abstract selected for Plenary Poster Session, American Society Bone and Mineral

Research Annual Meeting, Toronto. 2001 CaPCURE prostate cancer research award 2005 Astra-Zeneca Best Paper, Nature Publishing Group

MEMBERSHIP IN PROFESSIONAL SOCIETIES American Association for the Advancement of Science American Association of Cancer Research American College of Veterinary Internal Medicine American Geriatric Society American Veterinary Medical Association International Bone and Mineral Society


New York Academy of Sciences Oxygen Society The Gerontological Society of America Veterinary Cancer Society Endocrine Society Chinese Hard Tissue Society Chinese Cancer Society

TEACHING ACTIVITIES 2000-2002 PIBS Admissions Committee Immunology Representative Courses: Didactic: Course: Cell Molecular Biology 580, U. Michigan, 1999. Lecture: Oxidative stress-mediated induction of gene expression. Educational Goals: Detail mechanism through which oxidative stress induces gene expression. Effort: 1 hour contact time. Course: Pathology 580, U. Michigan, 1999. Lectures: The biology of oxidative stress. Educational Goals: Describe the basic biology of oxidative stress, how oxidative stress mediates damage, and induces signal transduction. Effort 6 hours contact time. Course: Advanced tumor biology, EVMS, 1997. Lecture: Anticancer molecular therapeutics. Educational Goals: Detail gene therapy strategies including methods of vector construction and methods of gene transfer (viral, mechanical, chemical, electrical). Detail methods of antisense technology. Describe experimental and clinical examples of antisense and gene therapy. Effort: 1.5 hours contact time. Course: Immunology Journal Club, EVMS, 1997 Educational Goals: Expose students to current literature in immunology, including tumor immunology, and develop critical reviewing skills. Effort: 1 hour of contact time Course: Geriatrics Curriculum, EVMS, 1997 Lectures: Biology of aging Educational Goals: Provide an overview of the theories of aging, including oxidative stress, telomeres, and cellular senescence. Effort: 12 hours contact time. Course: Environmental Toxicology, U. Wisconsin, 1995 Lecture: Tumor immunology Educational Goals: Detail basic tumor immunology including cytotoxic T-cell, natural killer cell, and tumor specific antigen biology. Effort: 2 hour contact time.


TEACHING ACTIVITIES (Cont’d) Course: Nutrition, U. Wisconsin, 1995 Lecture: Aging and immunology Educational Goals: Describe how the immune system changes with aging. Effort: 1 hour contact time. Course: Advanced Internal Medicine Review, U. Wisconsin, 1993 Lecture: Overview of genetics Educational Goals: Provide review of Mendelian genetics and introduce basic concepts of molecular genetics. Effort: 1 hour contact time. Course: Oncology, U. Wisconsin, 1992 Lectures: Hemostasis disorders Educational Goals: Instruct students on clinical presentation, diagnosis and treatment of bleeding disorders Effort: 2 hours contact time Course: Advanced Internal Medicine Review, U. Wisconsin, 1992 Lecture: Principles of immunodiagnostics Educational Goals: Provide overview of principles and practice of immunodiagnostic tests including, ELISAs, hemagglutination inhibition, and radial immunodiffusion assays. Effort: 1 hour contact time. Course: Advanced Internal Medicine Review, U. Wisconsin, 1991 Lecture: Disorders of calcium homeostasis Educational Goals: Describe pathophysiology of the hormonal axis that regulates calcium regulation. Effort: 1 hour contact time. Clinical: All at the School of Veterinary Medicine; U. Wisconsin. Course: Medical rounds senior veterinary students; Fall 1991 through Spring 1993 Educational Goals: Case management, Pathophysiology, Therapeutic options Effort: 2.5 hours daily Course: Oncology journal club; Fall 1991 through Spring 1993 Educational Goals: Expose senior students to current literature on clinical and basic research. Effort: 1 hour weekly Course: Veterinary Clinical Oncology Laboratory; 1992, 1993 Educational Goals: Instruct junior students on principles and practice of clinical oncology methods including bone marrow aspiration and biopsy techniques. Effort 6 hours yearly


Yang Shi Pre-Doctoral Prostate Cancer 2010-2011 (CoMentor with Dr. Xu Yong, Department of Urology, Second Hospital of Tianjin Medical University)

Chunyan Yu Pre-Doctoral Prostate Cancer 2010-2012 Lecturer, Tianjan Medical U. Yuan Jiang Pre-Doctoral Prostate Cancer 2011-2013 Research Fellow Tianjin Training Grants: 1999-2007 Biomedical Research Training for Veterinary Scientists Training Grant 1999-current Nathan Shock Center of Excellence in Basic Biology of Aging Training Grant 1999-current Immunology Training Program 1999-current Cellular and Molecular Biology Training Program 1999-current Urology Training Program

Student Level in Lab Research Area Period Current Level Jerdine Tan UROP Prostate cancer 2001-2002 UM Undergraduate Celimar Rodriguez UROP Prostate cancer 2001-2002 UM Undergraduate Fadeel Mahmood UROP Prostate cancer 2001-2002 UM Undergraduate Jeff Fielhauer UROP Prostate cancer 2001-2002 UM Undergraduate Neel Patel UROP Prostate cancer 2001-2002 UM Undergraduate Rachel Roberts UROP Prostate cancer Winter 2001 UM Undergraduate Bianca Gruber UROP Prostate cancer 2001-2002 UM Undergraduate Stephanie Bailey UROP Prostate cancer Winter 2001 UM Undergraduate Jennifer Rai UROP Prostate cancer Winter 2001 UM Undergraduate Monica Mahesh UROP Prostate cancer Winter 2001 UM Undergraduate Kara DeBoer UROP Prostate cancer Winter 2000 UM Undergraduate Mary Whitney UROP Prostate cancer Winter 2000 UM Undergraduate Bobbi Terelli UROP Prostate cancer Winter 2000 UM Undergraduate Brian Adams Undergradute Heat shock prot. Winter 2000 UM Undergraduate Bora Hong Undergraduate Prostate Cancer Fall 2000 Duke U. Undegraduate Avni Patel Undergraduate Bone Cancer Fall 2000 UM Undergraduate Radhika Devalaraja Post-Doctoral Bone Disease 2000-Current Pfizer/UM Post-Doctoral Richard Prebish Undergraduate General Training 2000-Current UM Undergraduate Eric Diez Undergraduate General Training 1999-2000 UM Undergraduate Rachel Ershler Undergraduate General Training 1999 UM Undergraduate Pete Smith Post-Doctoral Prostate Cancer 1999-2002 Associate Professor, Yale U. Jill Murtha Pre-Doctoral Oxidative Stress PhD 2003 Research Investigator, U.M. Jin-lu Dai Post-Doctoral Bone Disease 1999-Current Research Investigator, U.M. Zheng Fu Pre-Doctoral Prostate Cancer PhD 2002 Assistant Professor, Virginia

Commonwealth University Jian Zhang Pre-Doctoral Oxidative Stress PhD 2001 Director, Ctr for Translational

Research, Guangxi University Cristine Hart Pre-Doctoral Gerontology 1996-1998 Graduate Student Eastern Virginia

Medical School David Hall Postdoctoral Oxidative Stress 1996-1998 Research Scientist, Univ. of Iowa Allen Michael Postdoctoral Bone Disease 1996-1998 Research Fellow, Univ. of Wisconsin Shawn Parnell Med Student Prostate Cancer 1998 Medical School Rebecca Lipsey Med Student Prostate Cancer 1998 Medical School Patrick Lester Post-Doc Prostate Cancer 2002-2003 Research Fellow, ULAM Meghan Brennan Pre-Doctoral Prostate Cancer 2002-current UM Graduate Student (Pathology) Lauren Wallner Undergraduate Prostate Cancer 2003-current UM Undergraduate Lindsey Dehne Pre-Doctoral Prostate Cancer 2002-2003 Undergrad


2000-current Clinical Cancer Immunology Training Grant Summary of Keller Students: Graduate Student Committees other than Keller’s Students: 2000 Hen-Li Chen; Mentor Laurie McCauley; University of Michigan Dental School, PhD 2000 Maya Williams, Mentor Kathleen Collins; Cellular Molecular Biology 2011 Dani Burgeneske, Mentor Jeff MacKiegan, Van Andel Institute TEACHING ACTIVITIES (Cont'd) 2003 Keni Gu, Mentor: Bruce Rutherford, Dental School, PhD 2003 Mentor, Mark Day, 2003 Michael Fridman, Mentor: Kurt Hankenson, CMB Student’s Awards: 1996 Dave Hall; Outstanding Abstract Award for Paper Presentation: Eastern Virginia Medical School

Annual Research Conference. 1996 Jian Zhang; Annual Meeting Poster Award for Outstanding Geriatrics Research in Physiology,

Cellular and Molecular Biology. Am. Geriatric Society annual meeting. Chicago, IL 1997 Jian Zhang; Young Investigator Award. Oxygen Society Annual Meeting, San Francisco, CA. 1997 Dave Hall; Finalist for the George Sacher Award. Gerontological Society of America Annual

Meeting, Cincinnati, OH. 1997 Dave Hall; Platform Presentation: Eastern Virginia Medical School Annual Research Conference. 1998 Rebecca Lipsey, EVMS Student Assistantship in Oncology. "Oxidative stress-mediated

induction of interleukin-6 in prostate cells" 1998 Shawn Parnell, EVMS Student Assistantship in Oncology. "The mechanism of androgen-

mediated maintenance of IkBa in prostate cancer cells." 1998 Jian Zhang; Old Dominion University/EVMS Summer Student Research Grant. “Oxidative

stress-mediated induction of interleukin-6 in prostate cancer cells.” 1999 JinLu Dai; U. Michigan Cancer Center Summer Student Research Grant. “Role of interleukin-6

in prostate cancer bone metastases.” 2000 Jian Zhang: U. Michigan SPORE in Prostate Cancer. "Role of osteoprotegerin in prostate cancer,

J. Zhang" Student Grant. 2000 Zheng Fu: U.Michigan SPORE in Prostate Cancer. "Role of AKT kinase in androgen-

independent prostate cancer", Student Grant 2000 J. Zhang: Plenary Poster, Am Soc Bone Min Res. Annual Meeting. " Osteoprotegerin (OPG)

and anti-interleukin-6 (IL-6) antibody inhibit osteoclastogenesis induced by prostate cancer cells in vitro."

2001 Zheng Fu: Paper presentation, Am Assoc Cancer Res. Annual Meeting. “Identification of Raf Kinase Inhibitor Protein (RKIP) as a metastasis suppressor gene in prostate cancer skeletal metastasis.”

2001 Zheng Fu: Rachkham Travel Award 2001 Mary Whitney: UROP Summer Student Fellowship 2001 Mary Whitney: SPORE in Prostate Cancer, Summer Research Award 2001 Zheng Fu: SPORE in Prostate Cancer, Summer Research Award 2003 Jian Zhang: AACR Young Investigator Award. 2004 Zheng Fu: Poster recognized for Poster Discussion Session. INVITED PRESENTATIONS

“Gene therapy of cancer” invited seminar, American College of Veterinary Internal Medicine 12th Annual Meeting; San Francisco, CA, May, 1994.

“Dihydrotestosterone inhibits interleukin-6 promoter activation,” invited seminar, Geriatric Society of America Annual Meeting, Los Angeles, Nov., 1995.

INVITED PRESENTATIONS (Cont’d)


“Androgens, interleukin-6 and osteoporosis”, invited seminar, First Annual Conference on Immunology and Aging; National Institutes of Health Campus, June, 1996.

“Ethanol activation of the interleukin-6 promoter in bone marrow stromal cells,” invited seminar, Geriatric Society of America Annual Meeting; Washington, DC. Nov., 1996.

'“Steroid regulation of IL-6,” invited seminar, Gerontology Research Center, NIA, Baltimore, MD, Jan., 1997.

“Hormones and IL-6,” invited seminar, The Diabetes Institutes, Norfolk, VA, Jan., 1997. “Androgen regulation of IL-6 expression,” invited seminar, Dept. of Microbiology and Immunology,

EVMS, Feb., 1997. “TNF represses androgen responsiveness in LNCaP prostate cancer cells,” invited seminar, Virginia

Prostate Center, March 1998. “Aging and Gene Expression,” invited seminar, Department of Biochemistry, George Washington

University, March 1998. “Aging and Gene Expression” invited seminar, Unit for Laboratory Animal Medicine and the

Department of Pathology, University of Michigan. April, 1998. “IL-6: From lab bench to clinics,” invited seminar, Dept. of Veterinary Clinical Sciences, The Ohio

State U. April, 1998. “Regulation of Interleukin-6:Expression in aging bone and brain,” invited seminar, Parke-Davis

Pharmaceutical, Oct., 1998. “Cytokines and Prostate Cancer” invited seminar, Ann Arbor VA GRECC, Jan., 1999. “Crosstalk between cytokines and androgen receptor” UM SPORE in Prostate Cancer, Feb, 1999. “Osteoporosis and interleukin-6” invited paper, 3rd International Conference on Osteoporosis, Xian,

China, April, 1999. “Osteoporosis and interleukin-6” invited seminar, Tianjin Medical University, Tianjin, China, April,

1999. “The monkey model of osteoporosis,” invited seminar, Tianjin Geriatric Institute, Tianjin, China,

April 1999. “Interleukin-6 and prostate cancer,” invited seminar, Tianjin Cancer Institute, Tianjin, China, April

1999. “Oxidative stress-mediated regulation of interleukin-6 expression,” invited seminar, Dept. of

Physiology, UM, June 1999. “The role of interleukin-6 in prostate cancer pathophysiology,” invited seminar. Michigan

Consortium on Prostate Cancer Research, UM, March 2000. “Alcohol-mediated bone loss and interleukin-6,” invited seminar. Oral Health Sciences Seminar,

School of Dentistry, University of Michigan, April 2000. “Cross-talk between interleukin-6 and the androgen receptor,” invited seminar. East Medical

University, Shanghai, China, June 2000. “Cross-talk between interleukin-6 and the androgen receptor.” Invited seminar. Zhongshan Medical

University, Guangzhou, China, June 2000. "Skeletal Metastasis in Prostate Cancer." Invited seminar. Dept. of Urology. Kanazawa University,

Japan, October 2000." "Skeletal Metastasis in Prostate Cancer." Invited seminar. Dept. of Immunology. Tianjin Medical

University, Tianjin, China, October 2000." "Aging and cytokines." Invited seminar. Vaccines 2000 International Conference. Institute of

Advanced Studies Geriatrics and Gerontology. Washington, D.C., October, 2000. “Inflammatory cytokines.” Invited seminar. Anemia in Geriatrics Summit Meeting. Sponsored by

Amgen. Puerto Rico. February 2001. “The Biology of Skeletal Metastases” Invited seminar. Eastern Virginia Medical School, Norfolk,

VA. March 2001. INVITED PRESENTATIONS (Cont’d)

“The Biology of Skeletal Metastases” Invited seminar. American College of Veterinary Internal


Medicine. Denver, CO, May 2001. “Prostate Cancer Skeletal Metasis: Gene Array Analysis and Murine Models.” Invited Seminar.

Midwestern Bone Biology and Cancer Meeting, Indiana University, Bloomington, IN. May 2001. “Targeting Prostate Cancer Skeletal Metastasis.” Invited Seminar. Immunex Corporation. Seattle,

WA. June 2001. “Use of Gene Array to Identify A Prostate Cancer Metastasis Suppressor Gene.” Guanxi Medical

University, Nanning, China. June 2001. “Biology of Prostate Cancer Skeletal Metastasis” Invited Seminar, Genitourinary Conference,

University of Michigan, November, 2001. “Targeting Prostate Cancer Metastasis” Invited Seminar. University of Michigan, Nephrology Basic

Science Seminar, December, 2001. “Biology of Prostate Cancer Metastasis” Invited seminar. Institute of Gerontology, University of

Michigan, March, 2002. “Interleukin-6 and Prostate Cancer” Invited seminar. University of Innsbruck. Innsbruck, Austria.

March 2002. “Prostate cancer skeletal metastasis” Invited seminar. University of Innsbruck. Innsbruck, Austria.

March 2002. The Biology of Aging.” Invited seminar. Second International Conference on Aging. Washington,

D.C. June, 2002. “Introduction to Cancer Metastases” Invited Seminar. 32nd International Sun Valley Hard Tissue

Workshop. Sun Valley, Idaho August, 2002. “Applications of High Throughput Methods to Cancer Metastases” Invited Seminar. 32nd

International Sun Valley Hard Tissue Workshop. Sun Valley, Idaho August, 2002. “The biology of prostate cancer bone metastases” Invited seminar. Mt. Sinai Hospital, New York,

April 2003. “The biology of bone metastasis” Invited seminar. Van Andell Research Institute, Grand Rapids,

Michigan, August 2003. “Zebrafish as a model of aging.” Conference on Aquatic Animal Models of Human Disease,

Manassass, Virginia, Sept. 2003. “Cytokines in prostate cancer” 5th World Congress of Urology. London, England. Sept. 2003. “Prostate cancer-induced bone remodeling” Oral Health Sciences Seminar, U. Michigan. Oct. 2003. “The biology of prostate cancer skeletal metastases” 53rd Annual Meeting of the Central Division of

theJapan Urological Association. Kanazawa, Japan. Nov. 2003. “Methuselah’s secrets: Mining the mechanisms of aging” American College of Veterinary

Pathologists, Banff, Canada, Nov. 2003. “The biology of prostate cancer skeletal metastases” Paget’s Symposium. Houston, Texas,

December 2003. “RKIP as a target for metastasis” Signal Transduction as a therapeutic target annual meeting.

Luxembourg City, Luxembourg, January, 2004. “RKIP metastasis suppressor protein” Urologic Oncology Conference, U. Michigan, February 2004. “RKIP, a prostate cancer metastasis suppressor gene” Molecular Cancer Seminars, Medical College

of Ohio, February, 2004. “Targeting bone metastases” EISAI Pharmaceuticals, Andover, Massachusetts, February 2004. “The biology of skeletal metastases” Emory University. Atlanta, Georgia, April. 2004. “Prostate cancer metastasis” M.D. Anderson. Houston, Texas, Sept. 2004. “The biology of skeletal metastases” Amgen. Seattle, WA. Sept. 2004 “RKIP a metastasis suppressor gene” 9th World Congress on Advanced in Oncology, Crete, Greece.

Oct. 2004. “Interleukin-6: In health and disease” Pfizer. Ann Arbor, MI Oct 2004 INVITED PRESENTATIONS (Cont’d) “RKIP: A metastasis suppressor gene” Prouts Neck Prostate Cancer Conference, Prouts Neck, ME,

November, 2004.


“Bone morphogenetic protein-6 and osteoblastic prostate cancer metastases” InterProstate SPORE meeting, Houston, TX, January, 2005.

“Targeting bone metastases” TEM study section, Washington, DC, February, 2005. “Targeting interleukin-6 in prostate cancer” Centocor Advisors Board Meeting. Montpellier, France,

September, 2005. “The biology of prostate cancer bone metasases” University of Massachusetts, Boston,

Massachusetts, October, 2005. “The biology of prostate cancer bone metasases” Wayne State University, Detroit,

Massachusetts, November, 2005. “The biology of aging and cancer” American Society of Bone Marrow Therapeutics, Honolulu,

Hawaii, February, 2006. “The role of osteoclasts in prostate cancer bone metastses” Combined Bone/Cancer PO1 Meeting,

Seattle, Washington, February, 2006. “The biology of prostate cancer bone metastases” Department of Medicinal Chemistry, Purdue

University, West Lafayette, Indiana, March, 2006. “Bone metastasis in urological disesases” Department of Urology, Tianjin Medical University,

Tianjin , China. June 2007 “Bone metastasis and veterinary medicine” Merck Veterinary Scholar Program, Michigan State

University, August 2008 “Biology of bone metastasis” Meet-the-Expert Session, AACR-MRS annual meeting, Toronto,

Canada, August 2008. “Biology of prostate cancer bone metastasis” Department of Urology, Rochester University,

Rochester, NY, October 2008. “Biology of bone metastasis” University of Nebraska, Omaha, November 2008. “Biology of bone metastasis” Michigan State University, E. Lansing, MI. November 2008. “Zebrafish as an aging model.” Alternative Models of Aging Research, NIA, Bethesda, MD, June

2009 “Zebrafish in biogerontology.” Aging Postdoctoral Training Grant Seminar, University of Michigan,

Ann Arbor, MI, November 2009 "Role of Wnts in bone metastasis." American Association of Cancer Research Annual Meeting,

Washington DC, March 2010. “Biology of Prostate Cancer Bone Metastasis” First Tumor Microenvironement Conference. Nankai

University , Tianjin, China, June, 2010. “Targeting Wnt Pathway in Prostate Cancer”. Prostate SPORE Conference. Ft. Lauderdale, FL,

March 2011. “Wnts and bone metastasis.” Cancer and Bone Society. 2011 “The Bone Microenvironement: Does it Matter?”. American Society of Clinical Oncology. 2012 “Impact of the bone microenvironment on prostate cancer progression.” Second Tumor

Microenvironment Conference. Nankai University, Tianjin, China 2012.

COMMITTEE AND ADMINISTRATIVE SERVICE National 1995 ACVIM Oncology, Credentials Committee 1996 - present ACVIM Oncology Residency Training Committee 1997 - present National Scientific Advisory Council, American Federation Aging

Research 1998 - present Scientific Advisory Board, Institute for Advanced Studies in

Immunology and Aging 2005 - present Network of Healthcare Advisors, Editorial Board of Current Cancer

Drug Targets 2005 Prelim Committee for CMB Nate Lanning 2006 U. M. Urology Chair Search Committee


Regional

1996 University of Wisconsin Gene Therapy Working Group 1997 - 1998 Eastern Virginia Medical School Cancer Committee 1997 - 1998 Animal Care and Use Committee 1998 - present Colony for Aged Rodents Advisory Committee 1998 - 2005 Comparative Integrative Genomics Operating Committee 1999 - 2001 Chair, Jody C. Ungerleider Memorial Award Committee 1999 - 2002 Rackham Graduate Student Appeals Committee 2000 Grant Reviewer for OVPR.

2003 Organizer, Connective Tissue Oncology Retreat Regional

2005-2009 Chair, Urology Research Advisory Committee 2007 Organized Combined Emory, U. Washingtin and U.M. Bone Metastasis

P01 meeting 2007-2010 Co-Chair, Prostate SPOREs Skeletal Metastasis Working Group PATENTS Keller ET, Fu Z. Systems and methods for detecting and regulating metastasis. US Patent 7407763. August 5, 2008. Markovitz DM, Mor-Vaknin N, Keller ET, Hall CL, Hiniker SM. Compositions and methods for detecting cancer and inhibiting metastasis. US Patent 7641902. Jan 5, 2010. BIBLIOGRAPHY Completed Publications in Scientific Journals Peer-Reviewed Publications 1. Keller ET. Elevated trypsin-like immunoreactivity in a dog with exocrine pancreatic

insufficiency and chronic pancreatitis. J Am Vet Med Assoc;196:623-626, 1990. 2. Keller ET. Testing for exocrine pancreatic insufficiency in cats. (Letter). J Am Vet Med Assoc

197:1112-1114, 1990. 3. Keller ET, Madewell BR. Locations and types of neoplasms in immature dogs: 69 cases (1964-

1989). J Am Vet Med Assoc 200:1530-1532, 1992. 4. Keller ET, Vail DM. Intrapleural cisplatin as a cause of paroxysmal ventricular tachycardia.

(Letter). J Vet Int Med 6:198-199, 1992. 5. Keller ET. Immune-mediated disease as a risk factor for canine lymphoma. Cancer 70:2334-

2337, 1992. 6. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors

and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Int Med. 7:289-295, 1993.

7. Keller ET. Gene therapy for the dog. Veterinary Cancer Society Newsletter. 18(1), 10-11, 1994. 8. MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox

LE, Keller ET, Obradovich J, Madewell B, Rodriguez C, Kitchell B, Fidel J, Susaneck S, Rosenberg M. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Targeting. 2:391-3966, 1994.

9. Keller ET, Ershler WB. Effect of IL-6 receptor antisense oligodeoxynucleotide in vitro proliferation of myeloma cells. J Immunol. 154:4091-4098, 1995.

10. Kisseberth WC, MacEwen EG, Helfand SC, Vail DM, London CL, Keller ET. Response to


liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma. J Vet Int Med. 9:425-428, 1995.

11. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, Obradovich J, Fidel J, Rosenberg M. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res. 1:1595-1601, 1995.

12. Padgett GA, Madewell BR, Keller ET, Jodar L, Packard M. Inheritance of histiocytosis in Bernese mountain dogs. J Small Animal Practice. 36:93-98, 1995.

13. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee H, Wang C, Mizokami A. Androgen receptor: An overview. Crit Rev Euk Gene Trans. 5:97-125, 1995.

14. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Frontiers in Bioscience 1:59-69, 1996.

15. Keller ET, Chang C, Ershler WB. Inhibition of NFkB through maintenance of IkB levels contributes to dihydrotestosterone-mediated inhibition of the interleukin-6 promoter. J Biol Chem, 271:26267-26275, 1996.

16. Keller ET, Burkholder JK, Shi F, Pugh TD, McCabe D, MacEwen EG, Malter JS, Yang NS, Ershler WB. In vivo particle-mediated cytokine gene transfer into canine oral mucosa and epidermis. Cancer Gene Therapy 3:186-191, 1996.

17. Keller ET, Wanagat, J, Ershler, WB. The molecular and cellular biology of interleukin-6 and the interleukin-6 receptor. Frontiers in Bioscience, 1:340-357, 1996. (http://www.bioscience.org/ 1996/v1/d/keller2/htmls/340-357.htm)

18. Keller ET, Pugh TD, Sun WH, Ershler WB. Evaluation of ovariectomy and dehydro-epiandrosterone sulfate administration on interleukin-6 levels and B16 melanoma growth in mice. Age, 19:75-81, 1996.

19. Martinez E, Moore DD, Keller ET, Pearce D, Robinson V, Simons Jr, S, Sanchez E, Danielsen M. The Nuclear Receptor Resource Project. Nucl Acids Res, 25:163-165, 1997.

20. Keller ET. Of Mice and Women, Trends Endocrinol Metab, 8:327-328, 1997. 21. Keller ET, Zhang J, Ershler WB. Ethanol activates the interleukin-6 promoter in a human bone

marrow stromal cell line. J Gerontol: Biol Sci 52A:B311-317, 1997. 22. Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Develop Compar

Immunol 21:487-499, 1997. 23. Martinez E, Moore DD, Keller ET, Pearce D, Vanden Huevel JP, Robinson V, Simons Jr,

Gottlieb B, MacDonald P, Simons Jr, S, Sanchez E, Danielsen M. The nuclear receptor resource: a growing family. Nucl Acids Res 26:239-241, 1998.

24. Zhang J, Pugh TD, Stebler, B, Ershler WB, Keller ET. Orchiectomy increases bone-marrow interleukin-6 levels in mice. Calcif Tiss Int 62:219-226, 1998.

25. Sun WH, Keller ET, Stebler BS, Ershler WB. Estrogen inhibits phorbol ester-induced IB transcription and protein degradation. Biophys Biochem Res Com, 244:691-695, 1998.

26. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang N-S, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Human Gene Therapy, 9:1851-1861, 1998.

27. Binkley N, Ellison G, O'Rourke C, Hall D, Johnston G, Kimmel D, Keller ET. A rib biopsy technique for the cortical bone evaluation in rhesus monkeys (Macaca mulatta). Lab Animal Sci, 49:87-89, 1999.

28. Keller ET, Gravenstein SG. The Biology of Aging: Genetic and Immunologic Influences. In “Towards a Healthier Old Age”, Prous Science Telesymposium, http://www.prous.com/ts, 1999.

29. Chiu KM, Kiami PH, Schmidt MJ, Havighurst TC, Shug AL, Daynes RA, Keller ET, Gravenstein S. Correlation of serum L-carnitine and dehydroepiandrosterone sulfate (DHEAS) levels with age and gender in healthy adult people. Age Ageing, 28:211-216, 1999.

30. Chiu KM, Keller ET, Crenshaw TD, Gravenstein S. Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. Calcif Tissue Int. 64:527-533, 1999.


31. Keller ET, Binkley NC, Stebler BA, Hall DM, Johnston G, Zhang J, Ershler WB. Ovariectomy does not induce osteopenia through interleukin-6 in rhesus monkeys (Maccaca mulatta). Bone. 26:55-62, 2000.

32. Chiu KM, Arnaud CD, Ju J, Mayes D, Bacchetti P, Weitz S, Keller ET. Correlation of estradiol, parathyroid hormone, interleukin-6 and interleukin-6 receptor during the normal menstrual cycle. Bone. 26:79-85, 2000.

33. Knezevic-Cuca J, Stansberry KB, Johnston G, Zhang J, Keller ET, Vinik AI, Pittenger GL. Neurotrophic role of interleukin-6 and soluble interleukin-6 receptors in N1E-115 neuroblastoma cells. J Neuroimmunol. 102:8-16, 2000.

34. Ershler WB, Keller ET. Age-associated increased IL-6 gene expression, late life diseases and frailty. Ann Rev Medicine. 51:245-270, 2000.

35. Muenchen H, Lin DL, Walsh MA, Keller ET, Pienta KJ. TNF-induced apoptosis in prostate cancer cells through inhibition of NF-B by an IB “Super-Repressor.” Clin Cancer Res. 6:1969-1977, 2000.

36. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor- represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol. 164:800-805, 2000.

37. Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through interleukin-6 in mice. J Clin Invest. 106:887-895, 2000.

38. Morris MD, Tarnowski CP, Timlin A, Carden A, Dreier JL, Ignelzi MA Jr., Lin DL, Keller ET. Raman imaging as a probe of chemical and biomechanical properties of bone tissue. Proc. SPIE, 3918, 151-158, 2000.

40. Smith PC, Hobish A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine and Growth Factor Rev. 12:33-40, 2001.

41. Keller ET, Zhang J, Yao Z, Qi Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (Macaca mulatta) model of menopause. J Repro Immunol. 50:41-55, 2001.

42. Yao Z, Zhang J, Dai, J, Keller ET. Ethanol activates NFB DNA binding and p56lck protein tyrosine kinase in human osteoblast-like cells. Bone, 28:167-173, 2001.

43. Lin DL, Tarnowski CP, Patel AH, Rohn E, Morris MD, Keller ET. The bone metastatic LNCaP-derivative C4-2B prostate cancer cell line induces mineralization in vitro. Prostate, 47:212-221, 2001.

44. Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A. Longterm exposure of tumor necrosis factor- causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate, 46:319-326, 2001.

45. Zhang J, Dai J, Smith P, Qi Y, Lin D, Strayhorn C, Mizokami A, Fu Z, and Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone of mice. J Clin Invest, 107:1235-1244, 2001. PMCID: PMC209296.

46. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFB-inducing kinase activity. Antioxidant Redox Signaling, 3:493-504, 2001.

47. Richard V, Lairmore MD, Green PL, Feuer G, Erbe RS, Albrecht B, Keller ET, Dai J, Rosol TJ. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. Am J Pathology, 158:2219-2228, 2001.

48. Smith PC and Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate, 48:47-53, 2001.

49. Lin DL, M Whitney, Z Yao, Keller ET. Interleukin-6 induces androgen receptor activity through up-regulation of receptor expression in prostate cancer cells. Clin Cancer Res, 7:1773-1781, 2001.

50. Evan T. Keller, Jian Zhang, Carlton R. Cooper, Peter C. Smith, Laurie K. McCauley, Kenneth J. Pienta and Russell S. Taichman. Prostate carcinoma skeletal metastases: Cross-talk between


tumor and bone. Cancer Metastasis Reviews 20:333-349, 2001. 51. Fu Z, Dozmorov IM, Keller ET. Osteoblasts produce soluble factors that induce a gene

expression pattern in non-metastatic prostate cancer cells similar to that found in bone metastatic prostate cancer cells. Prostate, 51:10-20, 2002.

52. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today, 38:91-102, 2002.

53. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 62: 1832-1837, 2002.

54. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Min Res 17:1256-1263, 2002.

55. Demiralp, B., H. Chen, A.J. Koh-Paige, E.T. Keller, and L.K. McCauley. Anabolic effects of parathyroid hormone during endochondral bone growth are dependent on c-fos. Endocrinology 143:4028-4047, 2002.

56. Stewart S, Shea DA, Tarnowski CP, Morris MD, D Wang Franceschi R, Lin DL and E Keller, Trends in early mineralization of murine calvarial osteoblastic cultures. A Raman microscopic study. Journal of Raman Spectroscopy. 33: 536-543, 2002.

57. Keller ET. Overview of metastasis and metastases. Journal of Musuloskeletal Neuronal Interactions. 2:567-569, 2002.

58. Keller ET, Yao Z. Applications of high-throughput methods to cancer metastases. Journal of Musuloskeletal Neuronal Interactions. 2:575-578, 2002.

59. Fujita H, Koshida K, Keller ET, Takahasi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53:232-240, 2002.

60. Khorram O, Colman RJ, Kemnitz JW, Magness RR, Zhang J, Yao Z, Keller ET. The influence of sex hormones on circulating nitric oxide (NOx) levels in Rhesus monkeys (Macaca mulatta). Med Sci Monit 8:BR489-95, 2002.

61. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. Stromal factors involved in prostate carcinoma metastasis to the bone. Cancer (suppl) 97:739-747, 2003.

62. Keller ET and J. Brown JM. Osteoprotegerin (OPG), receptor activator of NFB ligand (RANKL) and RANK in cancer metastasis. Research Advances in Cancer 3:81-93, 2003.

63. McCauley LK, Tozum TF, Kozloff KM, Koh-Paige AJ, Chen C, Demashkieh M, Cronovixh H, Richard V, Keller ET, Rosol TJ, Goldstein SA. Transgenic models of metabolic bone disease: Impact of estrogen receptor deficiency on skeletal metabolism. Connect Tissue Res 44(Suppl. 1):250-263, 2003.

64. Murtha JM, Qi W, Keller ET.. Hematologic and serum biochemical values for zebrafish (Danio rerio). Comp Med 53:37-41, 2003.

65. Murtha JM, Qi W, Keller ET. Characterization of the Heat Shock Response in Mature Zebrafish (Danio rerio). Experimental Gerontol. 38:683-691, 2003.

66. Fu Z, Smith PC, Zhang L, Rubin M, Dunn RL, Yao Z, Keller ET. Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis. J Natl Cancer Inst.95:878-889, 2003. Has accompanying editorial.

67. Varani J, Fligiel H, Zhang J, Aslam MN, Lu Y, Dehne LA, Keller ET. Separation of retinoid-induced epidermal thickening from skin irritation. Arch Dermatol Res. 295:255-262, 2003.

68. Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Min Res. 18:1882-1888, 2003.

69. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate cancer progression in bone. Cancer Res. 63:7883-7890, 2003.

70. Kacergius T, Deng Y, Keller ET. Influenza virus and gamma interferon synergistically increase nitric oxide production in RAW 264.7 and AMJ2-C11 macrophages. Acta Medica Lituanica


10:174-184, 2003. 71. Lester PR, Keller ET. The comparative biology of skeletal metastasis. Vet Comp Oncol. 1:131-

139, 2003. 72. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS,

Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res. 64:994-999, 2004.

73. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 91:718-729, 2004.

74. Zhang J, Lu Y, O’brien CA, Dai J, Qi W, Hall DE, Manolagas SC, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: Evidence for free radical theory of aging. Experimental Gerontology.39:239-247, 2004.

75. Artz AS, Fergusson D, Drinka PJ, Gerald M, Bidenbender R, Lechich A, Silverstone F, McCamish MA, Dai J, Keller E and Ershler WB, Mechanisms of Unexplained Anemia in the Nursing Home. J Am Geriatr Soc 52:423-427, 2004.

76. Keller ET, Fu Z. Defining RKIP as a protein that regulates prostate cancer metastasis. Am J Urolog Rev 2:72-80, 2004. Accompanying commentary on pp 81-83.

77. Keller ET. Signal transduction pathways as therapeutic targets. IDrugs 7:217-222, 2004. 78. Zhang J, Lu Y, Dai J, Yao Z, Kitazawa R, Kitazawa S, Zhao X, Hall DE, Pienta KJ, Keller ET. In

vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Prostate 2004;59(4):360-369.

79. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagawa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279:17515-17523, 2004.

80. Keller, ET, Fu Z, Yeung K, Brennan M. Raf kinase inhibitor protein: A prostate cancer metastasis suppressor gene. Cancer Letters 207:131-137, 2004.

81. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64:765-771, 2004.

82. Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone JF, Aguzzi A, Ershler WB, Dai J, Fraser P, Hysloop PSG, Holtzman DM, Walker LC, Keller ET. Alzheimer Aß Vaccination of Rhesus Monkeys (Macaca mulatta) Mech Ageing Dev 125:149-151, 2004.

83. Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, Franceschi RT, D’Silva NJ, McCauley LK. Impact of Mitogen-activated Protein Kinase (MAPK) Pathway on Parathyroid Hormone Related Protein Actions in Osteoblasts. J Biol Chem 279:29121-29129, 2004.

84. Loberg RD, Fridman Y, Pienta B, Keller ET, McCauley L, Taichman R, Pienta KJ. Detection and isolation of circulating tumor cells in urologic cancer: A review. Neoplasia 6(4):302-9, 2004.

85. Keller ET, Fu Z, Brennan M. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68(6):1049-53, 2004.

86. Keller ET. Metastasis suppressor genes: A role for raf kinase inhibitor protein (RKIP). Anti-cancer drugs 15(7):663-9, 2004.

87. Gerhard GS, Malek RL, Cheng KC, Keller ET, Murtha J. Zebrafish, killifish, neither fish, both fish? (Letter) J Exp Gerontol 59(9):B873-B875, 2004.

88. Keller ET, Murtha JM. The use of mature zebrafish (Danio rerio) as a model for human aging and disease Compar Biochem Physiol 138(3): 335-341, 2004.

89. Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004;21(5):381-387.

90. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004;21(5):399-408.


91. Keller ET, Hall C, Dai J, Wallner L. Biomarkers of growth, differentiation, and metastasis of prostate epithelium. J Clin Lig Assay 27(2) 133-136, 2004

92. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94(2): 273-278, 2005.

93. Sun Y, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman N, Liang Z, Koh-Paige A, Shim H, Pienta K, Keller E, McCauley L, and Taichman RS. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Min Res 20(2): 318-329, 2005.

94. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146(4):1727-1736.

95. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 2005; 8(3): 253-259.

96. Hall CL, Bafico A, Dai J, Aaronson SA, and Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Priority Report. Cancer Res 2005; 65(17): 7554-7560.

97. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res. 2005 Oct 1;65(19):8818-25.

98. Dai J, Keller JM, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005; 65(18): 8274-85. PMID: 16166304.

99. Loberg RD, Logothetis CJ, Keller ET, and Pienta KJ. Pathogenesis and Treatment of Prostate Cancer Metastases: Targeting the Lethal Phenotype. J Clin Oncol, 2005; 23(32): 8232-41.

100. Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res, 2005; 65(23): 10921-10929. PMID: 16322239.

101. Hall C, Kang S, MacDougald OA, and Keller ET. Role of Wnts in prostate cancer bone metastases. J Cellular Biochem, 2006; 97(4): 661-672.

102. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn RL, Chinnaiyan AM, Yao Z, Keller ET. The metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate, 2006; 66(3): 248-256.

103. Ershler WB, Artz AS, and Keller ET. Issues of aging and geriatric medicine: Relevance to cancer treatment and hematopoietic reconstitution. Biol Blood Marrow Transplant, 2006; 12(1): 100- 106.

104. Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, and Chung LWK. Cancer interaction with the bone microenvironment. Amer J Pathology, 2006; 168(5): 1405-1412.

105. Beekman KW, Colevas AD, Cooney K, DiPaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CA, Smith D, Hussain M. Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rational and Study Design. Clinical Genitourinary Cancer, 2006; 4(4): 299-302.

106. Hall, CL, Dai JL, van Golen, KL, Keller ET, and Long MW. Type I collagen receptor (21) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res, 2006; 66(17): 8648-8654.

107. Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K, Namiki M. Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int J Urol 2006;13(5):593-600.

108. Hall CL, Keller ET. The role of Wnts in bone metastases. Cancer metastasis reviews 2006;25(4):551-8.

109. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller


ET. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer research 2006;66(6):3087-95.

110. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007; 24:69-78.

111. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. CCR2 expression correlates with prostate cancer progression. J Cell Biochem 2007.

112. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Keller ET, Yao Z, Zhang J. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 2007.

113. Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer research 2007;67(1):149-59.

114. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007;13(1):62-9. PMID: 17159986

115. Diehl KM, Keller ET, Ignatoski KM. Why should we still care about oncogenes? Mol Cancer Ther 2007;6(2):418-27.

116. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stromal-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007;292(3):C987-95

117. Lu, Y., Cai, Z., Xiao, G., Keller, E. T., Mizokami, A., Yao, Z., Roodman, G. D., and Zhang, J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res, 67: 3646-3653, 2007.

118. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M (2007): The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67:955-67.

119. Ilona Kryczek,* Shuang Wei,* Linhua Vatan,* June Escara-Wilke,† Wojciech Szeliga,*Evan T. Keller,† and Weiping Zou2*Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17_ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression. J. Immunol. 179:1423-26, 2007. Cutting Edge.

120. Keller, E. T., Dai, J., Escara-Wilke, J., Hall, C. L., Ignatoski, K., Taichman, R. S., and Keller, J. New trends in the treatment of bone metastasis. J Cell Biochem, 102: 1095-1102, 2007.

121. Keller, E. T., Rowley, D. R., Tomlins, S. A., Drake, C. G., Kantoff, P. W., Pienta, K. J., Montie, J. E., Carter, H. B., Hruszkewicz, A. M., Gomez, J., Mohla, S., and Getzenberg, R. H. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res, 67: 9613-9615, 2007

122. Karlsson, E.K., Baranowska, I., Wade, C.M., Salmon Hillbertz, N.H., Zody, M.C., Anderson, N., Biagi, T.M., Patterson, N., Pielberg, G.R., Kulbokas, E.J., 3rd, Comstock, K.E., Keller, E.T., Mesirov, J.P., von Euler, H., Kampe, O., Hedhammar, A., Lander, E.S., Andersson, G., Andersson, L., Lindblad-Toh, K., 2007. Efficient mapping of mendelian traits in dogs through genome-wide association. Nat Genet 39, 1321-1328.

123. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate. 2008 Jan 1;68(1):92-104. PMID: 18008334 [PubMed - indexed for MEDLINE]

124. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid Hormone Mediates Bone Growth through the Regulation of Osteoblast Proliferation and Differentiation. Bone 42:806-818, 2008. PMID18234576.

125. Havens AM, Pedersen EA, Shiozawa Y, Ying C, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, McCauley LK, Loberg RD, Pienta KP, Taichman RS. An in vivo mouse modle for human


prostate cancer metastasis. Neoplasia 10:371-380, 2008. PMID 18392141. 126. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC. Snail is a repressor of

RKIP transcription in metastatic prostate cancer cells. Oncogene 27:2243-2248, 2008. PMID: 17952120.

127. Keller JM, Escara-Wilke JF, Keller ET. Heat stress-induced heat shock protein 70 expression is dependent on ERK activation in zebrafish (Danio rerio) cells. Comp Biochem Physiol Part A 150: 307-314, 2008. PMID: 18467140 [PubMed - indexed for MEDLINE]

128. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y. Breast Cancer-derived Dickkopf1 Inhibits Osteoblast Differentiation and Osteoprotegerin Expression: Implication for Breast Cancer Osteolytic Bone Metastases. Int J Cancer 2008;123:1034-42. . PMID: 18546262

129. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008;68:1396-404. PMID: 18561248k.

130. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 2008 Jul;68(14):5785-94. PMID: 18632632

131. Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 2008 Aug;10:797-803. PMID: 18670640. PMCID: PMC2481569.

132. Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys 2008 Sep 1;72(1):153-60. PMID: 18722266. PMCID: PMC2597029.

133. Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 2008; June 1;68(8):820-9. PMID: 18324676.

134. Woods Ignatoski KM, Friedman J, Escara-Wilke J, Zhang X, Daignault S, Dunn RL, Smith DC, Keller ET. Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy. J Interferon Cytokine Res 2009 Feb;29(2):105-12. PMID: 19014338. PMCID: 2956618.

135. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, Hu CD. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 2008 Dec 1;68(23):9663-70. PMID: 19047143. PMCID: PMC3100895.

136. DeHaan AM, Wolters NM, Keller ET, Ignatoski KM. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate 2009;69(5):528-37. PMID: 19143022. PMCID: PMC2766509.

137. Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate. 2009 Aug 1;69(11):1222-34. PMID: 19434660 [PubMed - indexed for MEDLINE]

138. Mizokami A, Koh E, Isumi K, Narimoto K, Takeda M, Honma S, Dai J, Keller ET, Namili M. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of T and DHT from DHEA. Endocrine-Related Cancer 2009 Dec;16(4):1139-55. PMID: 19608712.

139. Li Y, Mizokami A, Izumi K, Narimoto K, Shima T, Zhang J, Dai J, Keller ET, and Mikio Namiki. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. Prostate 2010 Jan1;70(1):48-60. PMID: 19725034 [PubMed - as supplied by publisher]

140. Comstock KE, Hall CL, Daignault S, Mandlebaum SA, Yu C, Keller ET. A bioluminescent orthotopic mouse model of human osteosarcoma that allows sensitive and rapid evaluation of new therapeutic agents In vivo. In Vivo. 2009 Sep-Oct;23(5):661-8. PMID: 19779098 [PubMed - in process]


141. Jung Y, Shiozawa Y, Wang J, Wang J, Wang Z, Pedersen EA, Lee CH, Hall CL, Hogg PJ, Krebsbach PH, Keller ET, Taichman RS. Expression of PGK1 by prostate cancer cells induces bone formation. Mol Cancer Res. 2009 Oct;7(10):1595-604. Epub 2009 Oct 13.PMID: 19825988. PMCID: PMC2771860.

142. Mizokami A, Koh E, Izumi K, Narimoto K, Takeda M, Honma S, Dai J, Keller ET, Namiki M. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer. 2009 Dec;16(4):1139-55. Epub 2009 Jul 16. PMID: 19608712 [PubMed - in process]

143. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2010 Feb 11;29(6):811-21. Epub 2009 Nov 16. PMID: 19915614. PMCID: PMC2820596.

144. Bradley DA, Daignault S, Ryan CJ, DiPaola RS, Cooney KA, Smith DC, Small E, Matthew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs, 2010;29(6):1432-40. Erratum 2011Dec;29(6):1432-40. PMID 20336348. PMCID: PMC2917503.

145. Dai J, Lu Y, Yu C, Keller JM, Mizokami A, Zhang J, Keller ET. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res. 2010 Jun15;70(12):5014-23. PMID: 20501834. PMCID: PMC2888854.

146. Thudi ND, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ. Dickkopf-1 (DDK-1) Stimulated Prostate Cancer Growth and Metastasis and Inhibited Bone Formation in Osteoblastic Bone Metastases. Prostate 2011 May;71(6). PMID: 20957670. PMCID: PMC3025080.

147. Christopher L. Hall, Honglai Zhang, Shobun Baile, Mats Ljungman, Stuart Kuhstoss, and Evan T. Keller. p21CIP-1/WAF-1 Induction Is Required to Inhibit Prostate Cancer Growth Elicited by Deficient Expression of the Wnt Inhibitor Dickkopf-1 (DKK-1). Can Res. 2010 Dec 1;70(23):9916-26. PMID:21098705. PMCID: PMC3059079.

148. Keller ET, Li LY. The first Tianjin, China forum on tumor microenvironment. Cancer Res. 2011 Jan 15;71(2):310-3. Epub 2011 Jan 11. PMID: 21224351. PMCID: PMC3075440.

149. Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X, Keller ET. ALDH activity indicates increased tumorgenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo. 2011 Jan-Feb;25(1):69-76. PMID: 21282737.

150. Ramsay, AK, McCraken SRC, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, Nuttall RK, Seywright M, Marques R, Keller E, Leung HY. ERK5 Signalling in Prostate Cancer Promotes an Invasive Phenotype. British Journal of Cancer 2011 Feb 15;104(4):664-672. Epub 2011 Jan 25. PMCID: PMC3049582

151. Keller ET. Role of Raf Kinase Inhibitor Protein (RKIP) in Pathophysiology of Prostate Cancer. Forum on Immunopathological Diseases & Therapeutics. 2011 2(1), 89-94. PMID: 21984962. PMCID: PMC3187718

152. Zhao E, Wang L, Dai, J, Kryczek I, Wei S, Vatan L, Altuwaijri S, Sparwasser T, Wang G, Keller ET, Zou W. Regulatory T Cells in the Bone Marrow Microenvironment in Patients With Prostate Cancer. 2012 Mar 1;1(2):152-161. PMID: 22720236. PMCID: PMC3376984

153. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrea L, Keller E, McCauley L, Cho KR, Buckanovich RJ. Human Ovarian Carcinoma-Associated Mesenchymal Stem Cells Regulate Cancer Stem Cells and Tumorigenesis via Altered BMP Production. JClin Invest. 2011 Aug;121(8):3206-19. PMID: 21737876. PMCID: PMC3148732.

154. Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MVP, Bokhoven AV, Werbeck JL,


Simmns JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, Rosol TJ. Development of a Brain Metastatic Canine Prostate Cancer Cell Line. The Prostate. 2011 Sep;71(12):1251-63. Epub 2011 Feb 14. PMID: 21321976. PMCID: PMC3139788

155. Jensen A, Saito Y, Liao C, Dai J, Keller ET, Ahmadie HA-K, Hatché D, Usatyuk P, Yala S, Cervantes G, Natarajan V, Salgia R, Posadas E. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clinical Cancer Research. 2011 May 15;17(10):3112-22. Epub 2011 Mar 1. PMID: 21364031. PMCID: PMC3118405

156. Sottnik JL, Zhang J, Macoska JA, Keller ET. The prostate cancer tumor microenvironment. Cancer Microenvironment. 2011Dec;4(3):283-297. DOI 10.1007/s12307-011-0073-8. PMID: 21728070. PMCID: PMC3234329

157. Yu C, Yao Z, Jiang Y, Keller ET. Prostate cancer stem cell biology. Minerva Urologica e Nefrologica. 2012 Mar;64(1):19-34. PMID 22402315. PMCID: PMC3332041.

158. Joseph J, Shiozawa Y, Jung Y, Kim JK, Pedersen E, Mishra A, Wang J, Keller ET, Pienta KJ, Taichman RS. Disseminated Prostate Cancer Cells Have the Ability to Instruct Hematopoietic Stem and Progenitor Cells to Regulate Bone Phenotype. Molecular Cancer Research. 2012 Mar;10(3):282-92. PMID: 22241219. NIHMSID: NIHMS352371. PMCID: PMC3307952.

159. Shiozawa Y, Taichman RS, Keller ET. Detection and Isolation of Human Disseminated Tumor Cells in the Murine Bone Marrow Stem Cell Niche. Methods Molecular Biology. 2013; 1035:207-15. PMID: 23959994.

160. Jung Y, Shiozawa Y, Wang J, McGregor N, Dai J, Park SI, Berry JE, Havens AM, Joseph J, Kim JK, Patel L, Carmeliet P, Daignault S, Keller ET, McCauley LK, Pienta KJ, Taichman RS. Prevalence of Prostate Cancer Metastases Following Intravenous Inoculation Provides Clues into the Molecular Basis of Dormancy in the Bone Marrow Microenvironment. Neoplasia. 2012May;14(5):429-39. PMID: 22745589. PMCID: PMC3384430.

161. Shima T, Mizokami A, Miyaqi T, Kawai K, Izumi K, Kumaki M, Ofude M, Zhang J, Keller ET, Namiki M. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer. Prostate. 2012 May 1;72(16):1789-801. PMID: 22549914.

162. Escara-Wilke J, Yeung K, ET Keller. Raf kinase inhibitor protein (RKIP) in cancer. Cancer and Metastasis Reviews. 2012 Dec;31(3-4):615-20. PMID: 22684368.

163. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir PA, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC. Polycomb protein EZH2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer. Cancer Research. 2012 Jun 15;72(12):3091-104. Epub 2012 Apr 13. PMID: 22505648.

164. Schade GR, Keller J, Ives K, Cheng X, Rosol TJ, Keller ET, Roberts WW. Histotripsy Focal Ablation of Implanted Prostate Tumor in an ACE-1 Canine Cancer Model. J. Urology. 2012 Nov;188(5):1957-64. PMID: 22999534.

165. Sottnik JL, Hall CL, Zhang J, Keller ET. Wnt and Wnt Inhibitors in Bone Metastasis. BoneKey. 2012 Jul 4;1:101. PMID: 23951488. PMCID: PMC3727776.

166. Yu C, Shiozawa Y, Taichman, RS, McCauley LK, Pienta KJ, Keller ET. Prostate Cancer and Parasitism of the Bone Hematopoietic Stem Cell Niche. Critical Reviews in Eukaryotic Gene Expression 2012 ;22(2) 131-48. PMID: 22856431. PMCID: PMC3615416.

167. Zhang H, Wu J, Keller JM, Yeung K, Keller ET, Fu Z. Transcriptional regulation of RKIP expression by androgen in prostate cell. Cell Physiol Biochem. 2012;30(6):1340-50. PMID: 23095933.

168. Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Current Molecular Medicine. 2013 May;13(4):626-39. PMID: 23061677. PMCID: PMC3624036.

169. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal Cells in Tumor Microenvironment and Breast Cancer. Cancer Metastasis Rev. 2013 Jun;32(1-2):303-15. PMID: 23114846.


170. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, Wang J, Jin T, Zhang H, Dai J, Krebsbach PH, Keller ET, Pienta KJ, Taichman RS. Recruitment of Mesenchymal Stem Cells Into Prostate Cancer Promotes Metastasis. Nat Commun. 2013,4,1795. Doi: 10.1038/ncomms2766. PMID: 23653207. PMCID: PMC3649763.

171. Shin M, Mizokami A, Kim J, Ofude M, Konaka H, Kadono Y, Kitaqawa Y, Miwa S, Kumaki M, Keller ET, Namiki M. Prostate. 2013 Aug;73(11):1159-70. PMID: 23532895.

172. Tang Y, Rowe RG, Botvinick EL, Kurup A, Putnam AJ, Seiki M, Weaver VM, Keller ET, Goldstein SA, Begun D, Dai J, Saunders TL, Weiss SJ. Control of Mesenchymal Stem Cell Commitment by an MT1-MMP/YAP/TAZ Mechanotransduction Axix. Develomental Cell, 2013 May 28;25(4):402-16, PMID: 23685250. PMCID: PMC3736823.

173. Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double Blind Randomized Phase II Trial of Maintenance Sunitinib Versus Placebo Following Response to Chemotherapy for Patients With Advanced Urothelial Carcinoma. Cancer. 2013 Nov 18. PMID: 24249435.

174. Zhang H, Yu C, Dai J, Hua A, Sottnik JL, Shelley G, Hall CL, Park SI, Yao Z, Zhang J, McCauley LK, Keller ET. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-Catenin activation of the DKK1 promoter in prostate cancer. Oncogene. 2013 Jun 10. Doi: 10.1038/onc.2013.203. PMID: 23752183.

175. Osisami M, Keller ET. SPDEF: A molecular switch for E-cadherin expression that promotes prostate cancer metastasis. Asian J. Andrology. 2013 Sep;15(5):584-5. PMID: 23708459. PMCID: PMC3881650.

176. Osisami M, Keller ET. Mechanisms of Tumor Dormancy. J Clin Med. 2013, 2,136-150. ISSN 2077-0383.

177. Ofude M, Mizokami A, Kumaki M, Izumi K, Konaka H, Kadono Y, Kitagawa Y, Shin M, Zhang J, Keller ET, Namiki M. Repression of Cell Proliferation and Androgen Receptor Activity in Prostate Cancer Cells by 2’-Hydroxyflavanone. Anticancer Res. 2013 Oct;(10):4453-61. PMID: 24123015.

178. Shi J, Keller JM, Zhang J, Keller ET. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the Dickkopf family of Wnt inhibitors. J Hepatocellular Carcinoma. In Press

Books 1. The Biology of Bone Metastases. Keller ET. Editor, Chung L. Associate Editor. Kluwer

Academic Publishers. Boston, MA. 2004.

Chapters in Books 1. MacEwen EG, Keller ET. Current strategies for management of metastatic disease. In: Kirk RW,

ed. Current Veterinary Therapy XI, Philadelphia, W.B. Saunders, 427-432, 1992. 2. Cotter SM, Keller ET. Oncology. In: Pratt PW, ed. Review questions & answers for veterinary

boards, Goleta, CA, American Veterinary Publications, Inc., 191-202, 1993. 3. Keller ET, Helfand SC. Soft tissue sarcomas in the cat. In: August J ed. Consultations in feline

medicine. Philadelphia, W. B. Saunders, 557-566, 1994. 4. Kurzman I, Keller ET, MacEwen EG. New Developments in Cancer Therapy. In: Withrow SJ,

MacEwen EG, eds, Clinical Veterinary Oncology. 2nd ed. Philadelphia. W.B. Saunders, 147-166, 1995.

5. Keller ET. Mechanisms of bone resorption in prostate cancer skeletal metastases. In: Lucas, JN ed. Horizons in Cancer Research, Volume One: Prostate Cancer. Nova Publishers, 103-118, 2004.

6. Brown JM, Zhang J, Keller ET. OPG, RANKL, and RANK in cancer metastasis: expression and regulation. In: Keller ET and Chung L, Editors: The Biology of Bone Metastases. Kluwer Academic Publishers. Boston, MA. 2004.


7. Fu Z, Zhang L, Keller ET. Immunohistochemical expression of raf kinase inhibitor protein in prostate carcinoma. In: Hayat, MA ed. Handbook of Immunohisochemistry and in situ Hybridization of Human Carcinomas, V. 2: Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma, Elsevier Academic Press, 471-479, 2005.

8. Keller ET, Keller JM, Gillespie G. The use of mature zebrafish (Danio rerio) as a model for human aging and disease. In: Conn PM, ed. Handbook of Models for Human Aging, Burlington, MA, Elsevier Publications, 309-316, 2006.

9. Yung R, Keller ET, Zhang J. Aging and Immunity. In: Xi H-Z, ed. Chinese Textbook of Geriatrics and Gerontology, 2nd ed. Publisher of Peoples Public Health, China. In Press.

10. Keller ET. Biology and Therapeutic Basis of Prostate Cancer Bone Metastasis. In: Chung LW, Issacs WB and Hoekstra MF, eds. Prostate Cancer: Biology, Genetics and the New Therapeutics. Second Edition. Human Press, 175-192, 2007.

11. Keller ET. Raf kinase. In: Schwab M, ed. Encyclopedia of Cancer. Springer-Verlag, 2534-2536, 2008.

12. Keller ET and Hall CL. Pathophysiology of Prostate Cancer Bone Metastasis. In: William Douglas Figg, Sr., Cindy H. Chau, and Eric J. Small eds., Drug Management of Prostate Cancer. Springer. 2009 In press.

curriculum vitae personal data name: evan todd keller, … › ~etklab › personnel › resume ›...

Documents